EP1390390A4 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number
EP1390390A4
EP1390390A4 EP02799146A EP02799146A EP1390390A4 EP 1390390 A4 EP1390390 A4 EP 1390390A4 EP 02799146 A EP02799146 A EP 02799146A EP 02799146 A EP02799146 A EP 02799146A EP 1390390 A4 EP1390390 A4 EP 1390390A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02799146A
Other languages
German (de)
French (fr)
Other versions
EP1390390A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1390390A2 publication Critical patent/EP1390390A2/en
Publication of EP1390390A4 publication Critical patent/EP1390390A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02799146A 2001-03-21 2002-03-19 Human secreted proteins Withdrawn EP1390390A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/008277 WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
EP1390390A2 EP1390390A2 (en) 2004-02-25
EP1390390A4 true EP1390390A4 (en) 2009-07-08

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02760994A Withdrawn EP1379132A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications Before (6)

Application Number Title Priority Date Filing Date
EP02760994A Withdrawn EP1379132A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1379132A4 (en)
AU (6) AU2002363296A1 (en)
CA (7) CA2441702A1 (en)
WO (7) WO2002102994A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
EP1000084A4 (en) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 human secreted proteins
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EE200100372A (en) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK Protein and TWEAK Protein Receptor Antagonists and Their Use in the Treatment of Immune Diseases
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1364021A2 (en) 2000-10-31 2003-11-26 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP1573024A4 (en) * 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
WO2003033727A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
EP1997512B1 (en) 2002-04-09 2013-12-04 Biogen Idec MA Inc. Methods for treating TWEAK-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2339710T5 (en) 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Cells that coexpress vitamin K reductase and vitamin K dependent protein and use them to improve the productivity of said vitamin K dependent protein
PL2189523T3 (en) * 2003-10-14 2012-05-31 Baxalta Inc Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
EP1714154A2 (en) * 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
MXPA06012187A (en) 2004-04-22 2007-03-28 Agensys Inc Antibodies and molecules derived therefrom that bind to steap-1 proteins.
US8759305B2 (en) * 2004-09-01 2014-06-24 Dynavax Technologies Corporation Methods and compositions for inhibition of innate immune responses and autoimmunity
CA2579705A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
CA2579349A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
MX349285B (en) 2005-02-28 2017-07-20 Baxalta Inc Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression.
EP1861499A4 (en) 2005-03-15 2008-09-03 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins
ES2432564T3 (en) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Treatment and evaluation of inflammatory disorders
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2445882B (en) * 2005-09-01 2011-02-23 Florey Howard Inst Prophylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2083864A4 (en) 2006-11-07 2010-12-08 Merck Sharp & Dohme Antagonists of pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (en) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
US8017573B2 (en) * 2007-11-30 2011-09-13 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
JP2013509191A (en) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション AX1 and AX189PCSK9 antagonists and variants
CN102639150A (en) 2009-10-30 2012-08-15 默沙东公司 AX213 and AX132 PCSK9 antagonists and variants
EP2582398B1 (en) 2010-06-16 2016-04-13 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
US8871737B2 (en) 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3048479A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Gene editing of pcsk9
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
CN110719968A (en) * 2017-06-22 2020-01-21 宝洁公司 Film comprising a water-soluble layer and a vapor-deposited inorganic coating
CN110709174A (en) 2017-06-22 2020-01-17 宝洁公司 Film comprising a water-soluble layer and a vapor-deposited organic coating
US20230158174A1 (en) 2020-04-09 2023-05-25 Verve Therapeutics, Inc. Chemically modified guide rnas for genome editing with cas9

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU SHEAU YU ET AL: "Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1830 - 1845, XP002528150, ISSN: 0888-8809 *
LOH E D ET AL: "Molecular Characterization of a Novel Glycoprotein Hormone G-Protein-Coupled Receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 282, no. 3, 6 April 2001 (2001-04-06), pages 757 - 764, XP003002810, ISSN: 0006-291X *

Also Published As

Publication number Publication date
EP1379264A1 (en) 2004-01-14
WO2002102994A2 (en) 2002-12-27
EP1379132A2 (en) 2004-01-14
EP1423134A2 (en) 2004-06-02
EP1414845A2 (en) 2004-05-06
EP1381622A2 (en) 2004-01-21
CA2441702A1 (en) 2002-12-27
WO2003004622A2 (en) 2003-01-16
AU2002332391A1 (en) 2003-01-02
WO2002095010A2 (en) 2002-11-28
WO2002076488A1 (en) 2002-10-03
CA2441417A1 (en) 2002-11-14
WO2002090526A2 (en) 2002-11-14
WO2002102994A3 (en) 2003-07-24
WO2002102993A3 (en) 2004-03-25
EP1390390A2 (en) 2004-02-25
CA2441832A1 (en) 2002-12-27
EP1414845A4 (en) 2009-07-08
CA2441416A1 (en) 2003-01-16
AU2002326293A1 (en) 2003-01-02
WO2003004622A3 (en) 2004-02-19
CA2441840A1 (en) 2002-11-28
AU2002324424A1 (en) 2002-12-03
EP1404702A2 (en) 2004-04-07
EP1379264A4 (en) 2009-07-08
WO2003038063A2 (en) 2003-05-08
WO2002102993A2 (en) 2002-12-27
EP1379132A4 (en) 2009-07-01
EP1404702A4 (en) 2009-07-08
AU2002354719A1 (en) 2003-01-21
WO2002095010A3 (en) 2004-02-12
WO2003038063A3 (en) 2003-12-11
CA2441397A1 (en) 2002-10-03
WO2002090526A3 (en) 2003-10-30
AU2002363296A1 (en) 2003-05-12
AU2002320013A1 (en) 2002-11-18
CA2441755A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
EP1390390A4 (en) Human secreted proteins
EP1392817A4 (en) Human secreted proteins
EP1251863A4 (en) 22 human secreted proteins
AU2002361452A8 (en) Secreted proteins
GB0218205D0 (en) Human ZZAP1 protein
IL162598A0 (en) Secreted protein
AU2002232596A1 (en) Secreted human proteins
AU2002354803A8 (en) Secreted proteins
EP1368468A4 (en) 83 human secreted proteins
AU2003301843A8 (en) 157 human secreted proteins
EP1385977A4 (en) Secreted proteins
AU2001294719A1 (en) Secreted human proteins
EP1370651A4 (en) 70 human secreted proteins
EP1417224A4 (en) Secreted proteins
AU2002365153A1 (en) 41 human secreted proteins
EP1404807A4 (en) 20 human secreted proteins
AU2002246998A1 (en) 50 human secreted proteins
AU2002348034A8 (en) 16 human secreted proteins
AU2002254275A1 (en) Human secreted proteins
AU2002303843A8 (en) Secreted proteins
AU2003211136A8 (en) 6 human secreted proteins
AU2002253985A1 (en) 83 human secreted proteins
AU2002247189A1 (en) 70 human secreted proteins
AU2002332483A1 (en) 13 human secreted proteins
EP1443818A4 (en) Novel secreted proteins and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090904